BioSpace News Archive

Parexel today announced the appointment of Scott Smith, M.D., Ph.D. as Senior Vice President, Global Therapeutic Area Head – Hematology.

Onconova Therapeutics, Inc. today announced new preclinical data on narazaciclib in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting.

Silo Pharma, Inc. announced that it has commenced development of a novel formulation as a targeted prophylactic treatment, designated as SPC-15, intended for stress, anxiety, and PTSD.

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced promising new in vivo and in vitro data that support the potential of the company’s novel UNO therapy to treat various types of solid tumors as a single agent and in combination with checkpoint inhibitors.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the first patient has been treated with Lomecel-B™ in its Phase 2 clinical trial in patients with Aging-Related Frailty in Japan.

BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that its long awaited Acelluar Oxygen Carrier BXT-25 has been successfully tested in animals.

HotSpot Therapeutics, Inc. today announced the presentation of additional preclinical data on the Company’s casitas B-lineage lymphoma-B (CBL-B) program in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023.

Onchilles Pharma, a private biotech company developing novel cancer therapeutics that leverage myeloid biology, presented new preclinical data on N17350, a first-in-class biologic therapeutic inspired by ELANE, a protein found in neutrophils that is part of a newly discovered innate cancer-killing pathway.

Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2023.

Zucara Therapeutics Inc., today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for ZT-01 for the prevention of night-time (nocturnal) hypoglycemia in patients with Type 1 Diabetes (“T1D”).